Prosecution Insights
Last updated: April 19, 2026

Regend Therapeutics Co. Ltd.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
2
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
17781173 NEW USE OF REGEND001 CELL AUTOLOGOUS DELIVERABLE PREPARATION IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS TICHY, JENNIFER M.H. 1653 Final Rejection May 31, 2022
17619591 METHOD FOR CULTURING URINE-DERIVED KIDNEY STEM CELLS AND USE THEREOF SCHUBERG, LAURA J 1631 Non-Final OA Dec 16, 2021
17609571 CLINICAL-GRADE AUTOLOGOUS BRONCHIAL BASAL CELL, DELIVERABLE FORMULATION, AND PREPARATION PROCESS BEHARRY, ZANNA MARIA 1632 Final Rejection Nov 08, 2021

Managing Regend Therapeutics Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month